



SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/17		SERIAL NO.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam A. Peyman		GROUP	
				FILING DATE November 13, 2001			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A.A						
	A.B						
	A.C						
	A.D						
	A.E						
	A.F						
	A.G						
	A.H						
	A.I						
	A.J						
	A.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	A.L						
	A.M						
	A.N						
	A.O						
	A.P						
	A.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	A.R	Bressler, N.M.: Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration with Verteporfin: One-year Results of 2 Randomized Clinical Trials - TAP Report 1, <i>Ophthalmol.</i> 1999; 117: 1329-45					
	A.S	Bressler, N.M.: Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration with Verteporfin: Two-year Results of 2 Randomized Clinical Trials - TAP Report 2, <i>Ophthalmol.</i> 2001; 119: 198-207					
	A.T	The Choroidal Neovascularization Prevention Trial Research Group: Laser Treatment in Eyes with Large Drusen: Short-term Effects Seen in a Pilot Randomized Clinical Trial, <i>Arch. Ophthalmol.</i> , February, 2001; 119: 198-207					
EXAMINER				DATE CONSIDERED			
							
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.							